Annovis Bio, Inc. (ANVS): Form 8-K filed 2026-11-13

Accepted by EDGAR: 2026-11-13 16:24 ET
Event date: 2026-11-13
Accession no.: 0001104659-26-127094
Original filing: SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Annovis Bio reports third quarter results, financing and clinical trial updates

Annovis Bio reported a $0.22 basic and diluted net loss per common share for the quarter ended September 30, 2026, versus $0.37 a year earlier. It closed an offering with approximately $21.0 million in gross proceeds, expected to fund operations through the DUET-AD 6-month data readout in March 2027.

Basic and diluted net loss per common share was $0.22 for the three months ended September 30, 2026, compared to $0.37 a year earlier.
Cash and cash equivalents totaled $2.8 million as of September 30, 2026, compared to $19.5 million as of December 31, 2025.
On November 6, 2026, Annovis closed an underwritten public offering with gross proceeds of approximately $21.0 million.
DUET-AD is fully enrolled with 862 patients; topline results from its 6-month treatment period are expected in March 2027.

earningsequity offeringproduct

Items reported

Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

Type	Description	Document
8-K	FORM 8-K	tm2629728d1_8k.htm
EX-99.1	EXHIBIT 99.1	tm2629728d1_ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.